The Latest Journal Articles in Gastroenterology

1Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: A post hoc analysis of the Karmiris trialGut, April 28, 2015  Clinical Article
2FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE studyAnnals of Oncology, April 28, 2015  Clinical Article
3Integrin antagonists are effective and safe for Crohn’s disease: A meta-analysisWorld Journal of Gastroenterology, April 28, 2015  Full Text  Evidence Based Medicine
4Effect of amitriptyline and escitalopram on functional dyspepsia: a multi-center, randomized, controlled studyGastroenterology, April 28, 2015  Clinical Article
5Management of HCV in cirrhosisCurrent Gastroenterology Reports, April 28, 2015  Review Article
6Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infectionAlimentary Pharmacology and Therapeutics, April 28, 2015  Evidence Based Medicine  Review Article
7Incidence, pattern, and etiology of elevated liver enzymes in pediatric inflammatory bowel diseaseJournal of Pediatric Gastroenterology and Nutrition, April 28, 2015  Clinical Article
8Protein trafficking in colorectal carcinogenesis - targeting and bypassing resistance to currently applied treatmentsCarcinogenesis, April 28, 2015  Review Article
9Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destructionHepatobiliary Surgery and Nutrition, April 28, 2015  Full Text  Clinical Article
10How much do cancer-related symptoms contribute to health-related quality of life in lung and colorectal cancer patients? A report from the Cancer Care Outcomes Research and Surveillance (CanCORS) ConsortiumCancer, April 28, 2015  Clinical Article
1Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancerAmerican Association for Cancer Research News, April 28, 2015
2Oral milk thistle extract stops colorectal cancer stem cells from growing tumorsUniversity of Colorado Health News, April 28, 2015
3The past, present and future of pancreatic cancer research and treatmentCentro Nacional de Investigaciones Oncologicas News, April 28, 2015
4A CRISPR antiviral toolEmory's Woodruff Health Sciences Center News, April 28, 2015
5IL-33 promotes colorectal cancer tumor-growing environmentBaylor College of Medicine News, April 28, 2015
6Researchers launch first trial of standard vs. molecular therapy for pancreatic cancerGeorgetown University Medical Center News, April 28, 2015
7Altered bacteria may reduce inflammation and alleviate inflammatory bowel diseasesUF Health, April 27, 2015
8The intestine as the central organ in cases of food allergiesMedical University of Vienna, April 27, 2015
9Are hospitals doing all they can to prevent C. diff infections? Not yet, new study suggestsUniversity of Michigan Health System, April 27, 2015
10Genes influence survival in bowel cancer patientsCardiff University News, April 27, 2015

Show Me:

Risk factors for CHC-related death identified

As reported in the World Journal of Gastroenterology, the following risk factors for chronic hepatitis C (CHC)-related deaths have been identified (n=8250 CHC patients; n=144 CHC-related deaths): α-IFN therapy (AOR=0.53); liver cirrhosis (AOR=2.89); hepatocellular carcinoma versus CHC (AOR=8.82); hypertension (AOR=1.76); alcohol consumption (AOR=1.73); and HBsAg positivity (AOR=22.28).

KIT mutations associated with poor prognosis in GISTs

Based on a meta-analysis (18 studies; n=1487) reported in the World Journal of Surgical Oncology, KIT mutations in patients with gastrointestinal stromal tumors (GISTs) are associated with larger tumors (> 5 cm), higher mitotic activity (> 5), more frequent recurrences (OR = 2.06), more frequent metastases (OR = 2.77), and worse 3-year overall survival (OR = 0.47) compared to patients with PDGFRA mutations or wild-type.

Infliximab is effective in corticosteroid-refractory ulcerative colitis

As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.

Are YOU the Smartest Doc in America?

The Smartest Doc from MDLinx keeps you current with a competitive edge, pitting colleagues against one other for the title of The Smartest Doc in America.

Take the Challenge

Clinical Pearls

Clinical Pearl from Smartest DocImmunoserological tests can differentiate tropical sprue from celiac disease.

Clinical Pearl from Smartest DocLong-term diabetes is associated with decreased survival among patients with pancreatic cancer.

Clinical Pearl from Smartest DocSupraesophageal reflux disease is defined as reflux proximal to the upper esophageal sphincter.

Be Ready for Upcoming 2015 Board Exams!

Be prepared for board reviews with confidence with 1000s of board exam style questions. Prepare Here